A Parallel, Open-Label, Single-Dose Administration, Phase 1 Clinical Study to Assess the Safety and Pharmacokinetics of AD-104-A in Healthy Adult Volunteers and Patients With Renal Impairment
Latest Information Update: 06 Aug 2024
Price :
$35 *
At a glance
- Drugs AD 104 (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Addpharma
- 01 Aug 2024 Status changed from recruiting to completed.
- 30 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 30 Jan 2024 Planned primary completion date changed from 1 Nov 2023 to 1 May 2024.